Quest named exclusive independent lab provider for all Sentara Health Plans in Virginia and Florida

SECAUCUS, N.J and HAMPTON ROADS, Va., Sept. 18, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Sentara Health Plans, the health plan division of Sentara Health, an integrated, not-for-profit health care delivery system, today announced a multi-year strategic collaboration designed to expand access to high-quality, affordable and comprehensive laboratory testing for members of Sentara Health Plans.

SECAUCUS, N.J., Sept. 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of select laboratory assets from Allina Health.

The goal of the transaction is to improve access to high quality and affordable laboratory services for providers and patients in Minnesota and western Wisconsin. Financial details of the transaction were not disclosed.

SECAUCUS, N.J., Aug. 28, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on Friday, September 6, 2024, at 10:45 a.m. Eastern Time.

SECAUCUS, N.J. and TORONTO, Aug. 26, 2024 /CNW/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its acquisition of LifeLabs from OMERS. The transaction, valued at approximately CAN $1.35 billion (approximately USD $1 billion), including net debt, has received all necessary approvals and is now closed.

"This acquisition brings together two industry leaders committed to enhancing access to diagnostic innovation for patients in North America," said Jim Davis, Chairman, CEO, and President of Quest Diagnostics. "The combination of LifeLabs' strong business and deep community presence with Quest's specialized lab services and expertise creates a powerful opportunity to generate growth while improving care and outcomes for Canada's expanding and aging population."

SECAUCUS, N.J. and TORONTO, Aug. 26, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its acquisition of LifeLabs from OMERS. The transaction, valued at approximately CAN $1.35 billion (approximately USD $1 billion), including net debt, has received all necessary approvals and is now closed.

Transaction to broaden access to innovative, quality diagnostic information services powering affordable care in Ohio

SECAUCUS, N.J., and CLEVELAND, Aug. 21, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and University Hospitals, one of the nation's leading nonprofit health systems and academic medical centers, today announced a definitive agreement for Quest to acquire select assets of University Hospitals' outreach laboratory services business.

SECAUCUS, N.J., Aug. 15, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $400 million aggregate principal amount of its 4.600% senior notes due 2027 (the "2027 notes"), $600 million aggregate principal amount of its 4.625% senior notes due 2029 (the "2029 notes") and $850 million aggregate principal amount of its 5.000% senior notes due 2034 (the "2034 notes," and together with the 2027 notes and the 2029 notes, the "notes") under Quest Diagnostics' shelf registration statement. 

Lab tests offer insights for individuals who may experience inadequate intake of essential nutrients due to dietary restrictions, certain prescription medications, or chronic health conditions

SECAUCUS, N.J., Aug. 15, 2024 /PRNewswire/ -- Micronutrients are essential vitamins and minerals that are vital for well-being and disease prevention, but deficiencies can commonly be caused by food allergies and dietary restrictions, certain prescription medications, or chronic health conditions. At least one in three Americans are at risk of nutrient deficiencies1. Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the availability of 13 blood tests designed to evaluate micronutrient deficiencies, helping people identify if they are lacking certain vitamins and minerals needed by the body to maintain optimal health. These panels are now available for consumer purchase exclusively at questhealth.com.

SECAUCUS, N.J., Aug. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on October 21, 2024 to shareholders of record of Quest Diagnostics common stock on October 4, 2024.

About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from the world's largest database of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com. 

One in three women who tested positive for chlamydia or gonorrhea while pregnant were not retested before giving birth, despite potential to transmit infections to newborns

SECAUCUS, N.J., Aug. 12, 2024 /PRNewswire/ -- A new study by researchers from Quest Diagnostics (NYSE: DGX) and the University of Alabama suggests adherence to guideline-based laboratory testing and treatment of pregnant women for two of the most prevalent sexually transmitted infections (STIs) is suboptimal in the United States, with potentially dire effects on maternal and newborn health.

SECAUCUS, N.J., July 23, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2024.

Goal to broaden access to cost-effective and innovative laboratory services in Ohio

SECAUCUS, N.J. and COLUMBUS, Ohio, July 10, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and OhioHealth, a nationally recognized not-for-profit, charitable, integrated health system, today announced a definitive agreement for Quest to acquire select assets of OhioHealth's outreach laboratory services business.

SECAUCUS, N.J. and TORONTO, July 3, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a definitive agreement with OMERS to acquire LifeLabs, a trusted provider of community laboratory tests for millions of Canadians, for a value of approximately CAN $1.35 billion (approximately USD $985 million), including net debt.

SECAUCUS, N.J. and TORONTO, July 3, 2024 /CNW/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a definitive agreement with OMERS to acquire LifeLabs, a trusted provider of community laboratory tests for millions of Canadians, for a value of approximately CAN $1.35 billion (approximately USD $985 million), including net debt.